RLX (PD 139530) is a PI3K/Akt/FoxO3a signal inhibitor with anticancer activity against tumour cell lines such as colon cancer, inducing sub-G1 arrest and mitochondrial potential loss, thereby inhibiting tumour growth. RLX also exhibits antitussive and anti-asthmatic activity, reducing eosinophils and total lymphocytes in bronchoalveolar lavage (BAL) fluid, and exhibits toxicity toward A549 cells.
Molecular Weight:
214.26
Purity:
99.81%
CAS Number:
[4425-23-4]
Formula:
C13H14N2O
Target:
Others|||PI3K|||Akt|||FOXO
T24715
T24715
T24715
* VAT and and shipping costs not included. Errors and price changes excepted